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 Introduction 
 Currently, European guidelines recommend the pref-
erential use of MRI compared to CT for evaluation of the 
small bowel in patients with inflammatory bowel dis-
eases (IBDs)  [1] . Mainly, this choice of MRI over CT 
hinges upon the lack of exposure to radiation since, 
overall, these cross-sectional imaging modalities are 
comparable both in sensitivity and specificity in diag-
nosing inflammatory Crohn’s disease (CD) activity, fis-
tula, strictures and abscesses  [2–4] . A recent meta-anal-
ysis of 6 trials comparing MRI and CT revealed the 
pooled sensitivity and specificity for MR enterography 
(MRE) in detecting active CD to be 87.9% (95% confi-
dence interval (CI) 81.8–92.5) and 81.2% (95% CI 71.9–
88.4), respectively, compared to the pooled sensitivity 
and specificity of CT enterography (CTE) of 85.8% (95% 
CI 79.2–90.9) and 83.6% (95% CI 75.3–90.1), respective-
ly  [5] . All MREs were performed using a 1.5-T imager 
and 4 of the 6 CTEs were performed using a 64-detector 
row CT scanner except in 2 studies, which used a 16-row 
detector CT. The meta-analysis also revealed no differ-
ence in either sensitivity and specificity in detecting fis-
tula, strictures or abscesses. However, a significant het-
erogeneity of the studies was detected, which is almost 
certainly due to the fact that the studies used different 
criteria to define the severity and extent of inflammation 
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 Abstract 
 Diagnostic imaging techniques play an important role in the 
diagnosis and management of patients with inflammatory 
bowel diseases (IBDs). The approach should be guided by 
considerations of diagnostic accuracy, concerns about pa-
tient exposure to ionizing radiation, local expertise and tol-
erance of the endoscopic and/or imaging technique. In re-
gard to the clinical diagnostic value (sensitivity, specificity 
and accuracy), no significant differences exist between CT 
and MRI for the evaluation of the extent of inflammation, 
stricturing, penetrating disease or extraluminal complica-
tions such as abscesses. Due to the absence of radiation ex-
posure, MRI of the intestine is recommended as the first-line 
imaging modality in patients with suspected or established 
IBD. The focus of this review is the latest developments in 
MRI techniques to detect IBDs. Specifically, the use of new 
indices for the grading of inflammation or assessing bowel 
damage as well as innovative experimental approaches such 
as diffusion-weighted imaging or magnetization-transfer 
MRI to evaluate and quantify the degree of intestinal inflam-
mation and fibrosis in stricturing Crohn’s disease are dis-
cussed.  © 2015 S. Karger AG, Basel 
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since there are no single or even widely accepted radio-
logic scoring indexes of inflammation for cross-section-
al imaging results. The absence of a reproducible radio-
logical IBD index also signifies that the gastroenterolo-
gist strongly depends on the radiologist’s expertise in 
reading and interpreting pathological enterography re-
sults. Thus, gastroenterologists treating IBD patients 
should use the imaging techniques that are supported by 
the best local radiological expertise rather than simply 
follow the recommended guidelines.
 Aside from the advantage of being radiation-free, 
MRI also has a disadvantage compared to CT. MRI tech-
nology still requires significantly longer acquisition 
times. Therefore, in acute situations (e.g. acute abdo-
men) or in older patients or patients with difficulties 
holding their breath, CT is still the preferred imaging 
method  [1] . A recent study revealed that in CD patients 
(n = 53) with an acute onset of severe abdominal pain, 
the evaluation with a conventional abdominal 16-slice 
multidetector CT revealed findings similar to those ob-
tained with a dedicated MRE  [6] . Overall, the diagnosis 
of inflammation based on typical radiological signs of 
bowel wall thickening, stenosis of the lumen, increased 
contrast media uptake, enlarged local lymph nodes (>5 
mm in the short axis) and local mesenteric injection was 
not significantly different between CT (69.4%) and MRE 
(71.4%). Colonic inflammation was diagnosed in 30.2% 
of patients based on CT and in 29.0% of them based on 
MRE. The difference in the detection of lymph nodes was 
significant (CT: n = 49 and MRE: n = 27), whereas the 
differences between fistula (CT: n = 25 and MRE: n = 27) 
or abscesses (CT and MRE: n = 32) detection were not 
significant.
 MRI Scoring Systems of Inflammation 
 Classic radiologic signs of inflammation commonly 
used in MRI and CT cross-sectional imaging are bowel 
wall thickening, contrast wall enhancement and visible 
ulcerations ( table 1 ). However, a recent meta-analysis on 
MRE indications for the detection of inflammation and 
intestinal damage in CD has revealed a total of 22 signs to 
characterize inflammation  [7] . This illustrates the diffi-
culty to agree on a uniform index for evaluation of in-
flammation with MRI. Fourteen MRI-based disease ac-
tivity indices have been described and proposed  [8] . So 
far, only the Magnetic Resonance Index of Activity 
( MaRIA) has been externally evaluated and seems to have 
gained traction as an index for clinical studies  [9–12] . The 
MaRIA score is a composite score of pre- and post-con-
trast wall signal intensity for wall contrast enhancement, 
the thickening of the bowel and the presence of ulcers and 
edema. The score for a specific bowel segment (ileum, as-
cending colon, transverse colon, descending colon, sig-
moid and rectum) is calculated using the following, rath-
er complex, formula: 
 MaRIA (of a segment) =  (1.5 × wall thickening (mm)) + 
(0.02 × relative contrast en-
hancement) + (5 × edema) + 
(10 × ulceration).
 The global MaRIA score is then computed as the sum 
of the segmental MaRIA scores. The MaRIA score corre-
lates with an endoscopic score of intestinal inflammation 
(CD Endoscopic Index of Severity (CDEIS)) and is also 
moderately correlated with the Harvey-Bradshaw index 
Table 1.  Published prospective and retrospective studies comparing CT and MRI in the evaluation of patients 
with IBD MRI signs of bowel inflammation and/or damage [7]
General radiological signs (also applied in CT) Specific MRI signs
Abscess
Comb sign (prominent mesenteric vasculature in 
an inflamed segment)
Fat edema
Fibro-fatty proliferation
Free fluid
Lymph node size and number
Mucosal lesions
Stricture (decrease in bowel lumen with or 
without prestenotic dilation)
Wall thickness
ADC
DWI hyperintensity
Enhancement kinetics after gadolinium 
administration (e.g. wall enhancement, fat or lymph 
node enhancement)
Motility (using MRI cinematography)
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and C-reactive protein as a serologic marker of disease 
activity  [9] . More recently, this score was used to measure 
response to therapy and mucosal healing in patients with 
CD  [12] . In this 4-center Spanish study, 48 patients with 
active CD (CD Activity Index >150) confirmed by ileoco-
lonoscopy (CDEIS  ≥ 7 and presence of ulcers in at least 
one segment) were treated with either corticosteroids 
(n = 14, 29.2%) or agents that acted as antibodies to tumor 
necrosis factor (n = 34, 70.8%), for 12 weeks. MRI and 
ileocolonoscopy were performed before and after the 
treatment. The prediction of ulcer healing on a per seg-
ment basis with a segmental MaRIA <11 had a sensitivity, 
specificity, positive predictive value, negative predictive 
value and accuracy of 94, 69, 94, 67 and 90%, respectively. 
Mucosal healing could be predicted similarly with a seg-
mental MaRIA score of <7 with a sensitivity, specificity, 
positive predictive value, negative predictive value and 
accuracy of 85, 78, 92, 63 and 83%, respectively. The find-
ings suggest that this index might facilitate a non-invasive 
evaluation of mucosal healing in clinical trials. Addition-
ally, in case mucosal healing becomes an established ther-
apeutic goal in clinical practice, a recurrent evaluation 
with MRI to evaluate both the small and large intestines 
for ongoing inflammation seems to be more feasible and 
safer than recurrent ileocolonoscopies. However, from 
the practical standpoint, it is important to note that for a 
complete assessment of both the small and large bowels, 
the patient not only needs to be prepped with oral con-
trast but a rectal enema also needs to be applied for co-
lonic distension (800–1,500 ml volume). Without colon-
ic distension by the application of an enema, the diagnos-
tic accuracy in evaluating the colonic mucosa for 
inflammatory lesions and strictures significantly decreas-
es. As has recently been shown by Friedrich et al.  [13] , the 
sensitivity in detecting colonic inflammation decreases 
from 79% with a specificity of 96% with an water enema 
application to a sensitivity of 38% and specificity 99%, 
respectively, without the water application. However, 
whereas rectal enemas in the setting of MRI and CT ex-
aminations are often applied in Europe, these are not very 
welcomed in radiologic centers in the USA due to the 
need for enema application on the examination table, 
which results in longer examination times and the risk of 
incontinence, which then necessitates time-consuming 
room cleaning (Loftus and Herfarth, personal communi-
cation).
 More recently, a scoring system to evaluate disease 
progression by assessing structural bowel damage, in-
cluding stricturing lesions, penetrating lesions and surgi-
cal resection, (the Lemann Index) has been evaluated in a 
multicenter study  [14] . This system is based mainly on 
MRI/MRE imaging results and may in the future facilitate 
the evaluation of the efficacy of therapies in reversing or 
halting bowel damage. However, the score has yet to be 
validated independently, and the reproducibility of the 
MRI scoring system has to be confirmed across multiple 
sites  [15] . Given the high costs of MRI (at least in the USA, 
MRI is significantly more expensive than CT), it would 
also be desirable if the Lemann score could be reproduced 
using low-dose radiation CT imaging.
 New Developments in IBD MRI Diagnostics: 
Diffusion-Weighted MRI 
 A specific MRI technology is the diffusion-weighted 
imaging (DWI). The quantitative measurement for this 
technology is termed ‘apparent diffusion coefficient’ 
(ADC). The DWI technology, which was initially used in 
neuroimaging, depicts differences in the motion of water 
molecules in body tissues  [16] . The ADC value and thus 
the mobility of water molecules decrease with increased 
tissue cellularity such as inflammation or malignancy. 
The ADC value may also be used to grade tissue differen-
tiation as shown recently in patients with rectal cancer 
 [17] . The ADC significantly decreased with poorer dif-
ferentiation of the cancer.
 Several studies have evaluated the application of DW-
MRI in IBD  [11, 16, 18–25] . Overall it seems that the clin-
ical value of DWI in addition to a conventional MRI or 
MRE still requires further elucidation, but the studies 
published thus far point toward several additional advan-
tages of incorporating DWI to the standard MRI ( table 2 ). 
Kim et al.  [16] studied 55 patients with suspected CD pro-
spectively using conventional MRI and DWI and com-
pared the findings to ileocolonoscopy results. Of these, 44 
patients were finally diagnosed with CD. Overall, the sen-
sitivity for detecting mild inflammation in this study was 
increased with DWI compared to conventional MRI; 
however, the specificity was lower, especially, in the col-
orectum ( table 3 ). The authors discuss that the low speci-
ficity might be due to the fact that the study was performed 
Table 2.  Potential advantages of added DWI compared to only 
‘conventional’ MRI
No need for oral or intravenous contrast
Quantification of inflammation (potential biomarker)
Characterization of inflammation versus fibrosis (using ADC)
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without rectal contrast similar to a previous DWI study in 
CD patients, which also reported increased sensitivity in 
the detection of inflammation using DWI but a specificity 
of 62%  [23] . A study similar to the one performed by 
Friedrich et al.  [13] comparing conventional MRI with 
and without rectal enema seems to be warranted for fur-
ther evaluation of the clinical application of DWI. Pilot 
studies have also shown that DWI and ADC may be used 
to quantify intestinal inflammation and characterize the 
degree of fibrosis in stenotic disease  [11, 19, 21, 25] .
 Evaluation of Strictures in CD 
 Around 30–50% of all CD patients develop stricturing 
bowel disease during the course of their illness. These 
strictures are characterized initially by an inflammatory 
component; however, in the setting of prolonged inflam-
mation, excessive production of extracellular matrix 
components occurs and strictures become fibrotic over 
time  [26] . CT and MRI have sensitivities in the range of 
90% to detect strictures with and without prestenotic di-
lation, but so far no imaging modality can reliably evalu-
ate the extent of fibrosis. Also, the addition of positron 
emission tomography to CT or MRI has so far not 
achieved a clinically usable differentiation of inflamma-
tion versus fibrosis in strictures  [27] . However, the tech-
nology of MRI is further evolving and might offer the di-
agnostic accuracy for the delineation between inflamma-
tion and fibrosis in the bowel wall in the near future.
 Rimola et al.  [28] recently evaluated the value of differ-
ent MRI variables to predict fibrosis and inflammation in 
comparison with histology in a retrospective analysis of 
41 patients undergoing elective surgery for bowel resec-
tion. They found that inflammation correlated signifi-
cantly with the following 4 parameters: hypersignal on 
T2, mucosal enhancement, ulcerations and blurred mar-
gins. The degree of fibrosis correlated with 3 MRI param-
Table 3.  Sensitivity and specificity in detection of inflammation by DWI MRE compared to conventional MRE 
(ND; not done) [16]
Sensitivity  Specificity
MRI, % MRI + DWI, % p value M RI, % MRI + DWI, % p value
Inflammation 62 83 <0.001 94 60 <0.001
Deep ulcers 97 97 ND ND
Aphthae, erythema,
edema 18 62 <0.001 ND ND
Location inflammation
Terminal ileum 91 94
Colorectum 45 76 <0.001 96 57 <0.001
Normal signal
intensity on T2
High signal intensity
of T2
Low inflammation
Low fibrosis (n = 11)
Low inflammation
Marked fibrosis (n = 5)
Severe inflammation
Low fibrosis (n = 15)
Severe inflammation
Marked fibrosis (n = 13)
???????????????????
gain 70 s–7 min
???????????????????
gain 70 s–7 min
 Fig. 1. Proposed MRI predictors for the de-
gree of inflammation and fibrosis in resect-
ed Crohn’s intestinal segments. 
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eters: percentage of enhancement gain, the pattern of en-
hancement at 7 min and the presence of stenosis. They 
proposed a model that, based on these parameters, was 
able to predict the degree of inflammation and fibrosis in 
a strictured segment ( fig.  1 ). These parameters should 
now be evaluated in a multicenter prospective study with 
a unified imaging protocol. In such a prospective study, 
the comparability of the imaging results of MRI scanners 
from different manufacturers can also addressed, since 
the results may be quite different as shown in the past in 
other specialties such as oncology  [29] .
 Other technologies to evaluate strictures are DWI (see 
above) and ‘magnetization transfer’ (MT)-MRI  [30] . 
Whereas DWI centers on the mobility of water molecules 
in the context of the surrounding tissue, MT-MRI focus-
es on the interactions between the protons of free water 
and those of large immobilized macromolecules, such as 
collagen or immobilized phospholipid cell membranes in 
tissue  [31] . Animal experiments using the purified pepti-
doglycan-polysaccharide rat colitis model have demon-
strated the feasibility of MT-MRI in measuring the degree 
of intestinal fibrosis  [32–34] . Initial data in patients con-
firm the potential of this imaging modality in revealing 
significant differences of the MT ratio in gut segments 
with fibrosis compared to normal or inflamed tissue  [35, 
36] .
 Summary 
 In the last decade, MRI has been established as the pre-
ferred imaging technology in patients with IBD. Gener-
ally recognized scores for assessing the degree and extent 
of inflammation, such as the MaRIA score or the Lemann 
score, have been proposed and should now be broadly 
validated to assure reliability and reproducibility. Tech-
nologies, such as DWI and MT-MRI, are promising en-
deavors that add information to conventional MRI scans 
in IBD. Further validation of these technologies is neces-
sary, but these technologies may be able to quantify the 
degree of inflammation and fibrosis in the near future.
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